Efficacy News and Research

RSS
VIVUS seeks marketing approval of QNEXA in the EU

VIVUS seeks marketing approval of QNEXA in the EU

Chelsea completes successful NORTHERA pre-NDA assessment with FDA

Chelsea completes successful NORTHERA pre-NDA assessment with FDA

Novartis' Gilenya uptake to increase

Novartis' Gilenya uptake to increase

Inspire's denufosol tetrasodium TIGER-1 Phase 3 trial for CF published in AJRCCM

Inspire's denufosol tetrasodium TIGER-1 Phase 3 trial for CF published in AJRCCM

4SC AG's Phase IIb study evaluates efficacy of vidofludimus in RA patients

4SC AG's Phase IIb study evaluates efficacy of vidofludimus in RA patients

FDA approves Medtronic's Arctic Front Cardiac CryoAblation Catheter system for drug refractory PAF

FDA approves Medtronic's Arctic Front Cardiac CryoAblation Catheter system for drug refractory PAF

RXi's dermal anti-scarring candidate selected to advance into development

RXi's dermal anti-scarring candidate selected to advance into development

Taiho receives CHMP positive opinion on Teysuno in combination with cisplatin for advanced gastric cancer

Taiho receives CHMP positive opinion on Teysuno in combination with cisplatin for advanced gastric cancer

Diagenic, Pfizer enter collaboration to identify biomarkers in early stages of Alzheimer's disease

Diagenic, Pfizer enter collaboration to identify biomarkers in early stages of Alzheimer's disease

23andMe project aims at validating highly scalable pharmacogenomics research

23andMe project aims at validating highly scalable pharmacogenomics research

Viron's Phase 2a trial for VT-111 meets primary, secondary endpoints in ACS patients

Viron's Phase 2a trial for VT-111 meets primary, secondary endpoints in ACS patients

Alnylam Pharmaceuticals progress in delivery and translation of RNAi therapeutics

Alnylam Pharmaceuticals progress in delivery and translation of RNAi therapeutics

Repros prepares for dosing 3 mg cohort in low dose Proellex study in uterine fibroids and endometriosis

Repros prepares for dosing 3 mg cohort in low dose Proellex study in uterine fibroids and endometriosis

Bayer's SAFYRAL oral contraceptive receives FDA approval

Bayer's SAFYRAL oral contraceptive receives FDA approval

Anacor Pharmaceuticals initiates AN2690 phase 3 program for onychomycosis fungal infection

Anacor Pharmaceuticals initiates AN2690 phase 3 program for onychomycosis fungal infection

Genetic breakthrough in lung cancer

Genetic breakthrough in lung cancer

Manhattan Pharmaceuticals reports preliminary results from AST-915 Phase 1/2 study in essential tremor

Manhattan Pharmaceuticals reports preliminary results from AST-915 Phase 1/2 study in essential tremor

Omega-3 EPA or combination of EPA and DHA provide clear antidepressant benefits

Omega-3 EPA or combination of EPA and DHA provide clear antidepressant benefits

Amarin completes patient randomization in AMR101 Phase 3 trial in patients with high triglyceride levels

Amarin completes patient randomization in AMR101 Phase 3 trial in patients with high triglyceride levels

Boehringer Ingelheim's selection of development candidate triggers € 6.5 million milestone payment to Orexo

Boehringer Ingelheim's selection of development candidate triggers € 6.5 million milestone payment to Orexo

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.